Breakthrough: Regenerative Islet Transplantation Cures Type 1 Diabetes

Regenerative Islet Transplantation

A groundbreaking achievement in diabetes treatment has been reported from China. A collaborative team led by Professor Yin Hao from Shanghai Changzheng Hospital and Professor Cheng Xin from the CAS Center for Excellence in Molecular Cell Science has successfully cured Type 1 Diabetes (T1D) using minimally invasive transplantation of stem cell-derived “regenerative islets.”

This study, published in the prestigious journal The Lancet Diabetes & Endocrinology, offers real hope for a functional cure for millions of patients currently dependent on lifelong insulin therapy.

From “Lifelong Injections” to “Functional Restoration”

Type 1 Diabetes has long been considered an irreversible chronic condition. Because the body’s immune system mistakenly attacks and destroys insulin-producing β-cells in the pancreas, patients lose the ability to regulate blood sugar naturally. They must rely on external insulin injections every day to survive, facing constant risks of severe complications such as kidney failure, blindness, and cardiovascular disease.

While traditional islet transplantation can treat T1D, it is severely limited by the scarcity of donor organs. The core breakthrough achieved by the Chinese team is solving the “seed” problem—enabling the scalable regeneration of human islet tissue.

Key Technological Innovations

  1. Novel “Endoderm Stem Cell” (EnSC) Technology: Instead of using traditional induced pluripotent stem cells (iPSCs), the team established a new system based on “Endoderm Stem Cells.”
    • Precision: These cells are like starting from a specific branch of the developmental tree, differentiating only into targeted cells like pancreatic or liver cells.
    • Efficiency: The differentiation process is streamlined from 10 steps to just 2, shortening the production cycle from 40 days to 14 days.
    • Safety: Crucially, these cells do not proliferate indefinitely in the body, eliminating the tumor formation risks associated with other stem cell therapies.
  2. E-islet (Regenerative Islets): Using this technology, the team constructed “E-islet” tissues. Clinical data demonstrated that transplantation of these regenerative islets—whether derived from the patient (autologous) or a donor (allogeneic)—successfully rebuilt islet function.

Clinical Results: Insulin Independence Achieved

The results for T1D patients receiving this treatment have been remarkable:

This signifies not just disease management, but a physiological repair of organ function—a true “functional cure.”

What Does This Mean for Patients?

For the global diabetes community, this technology represents a pivotal shift:

  1. Unlimited Supply: By bypassing the need for deceased donor organs, stem cell technology can theoretically provide an unlimited supply of “regenerative islets” for all patients in need.
  2. Enhanced Safety: The new EnSC technology significantly reduces safety concerns compared to previous stem cell approaches.
  3. Broader Application: While currently focused on T1D, this technology holds immense potential for patients with severe Type 2 Diabetes who have lost islet function.

Future Outlook

Currently, the therapy requires immunosuppression to prevent autoimmune recurrence in allogeneic transplants. Future research aims to develop “universal” regenerative islets that can evade immune detection, making the cure even more accessible.

With Shanghai accelerating its biomedical innovation ecosystem, we are moving closer to a world where diabetes is no longer a lifelong sentence.

Based on reports from the Chinese Academy of Sciences and CCTV News. Source: https://www.cas.cn/cm/202603/t20260312_5103981.shtml

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Please consult a qualified healthcare professional for any medical decisions.